Novo Nordisk World Diabetes Foundation Pledge: Inside the $200M, 10-Year Commitment
Novo Nordisk commits US$200M over 2027-2036 to the World Diabetes Foundation for care in low- and middle-income countries. The numbers, track record and strategy.
Tag: Novo Nordisk
Read More
Novo Holdings Commits USD 100 Million Investment in Asceneuron
Novo Holdings has announced a $100 million investment in Swiss biotech firm Asceneuron, aimed at accelerating the development of innovative treatments for neurodegenerative diseases. This strategic funding highlights the potential impact of Asceneuron’s research on the biotech industry and patient care.